Quick Answer
Journey Medical Corp reported Total Revenue of $61.86 million for fiscal year 2025.
Journey Medical Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $61.86M +10.2% |
$56.13M -29.1% |
$79.18M +7.5% |
$73.67M +16.7% |
$63.13M +41.8% |
$44.53M |
| Revenue (ASC 606) | $61.24M +11.1% |
$55.13M -7.6% |
$59.66M -16.0% |
$71.00M +12.5% |
$63.13M +41.8% |
$44.53M |
| Net Income | -$11.43M +22.1% |
-$14.67M -280.8% |
-$3.85M +87.0% |
-$29.63M +32.7% |
-$43.99M -932.7% |
$5.28M |
| Diluted EPS | -$0.47 +34.7% |
-$0.72 -242.9% |
-$0.21 +87.6% |
-$1.69 +60.9% |
-$4.32 -981.6% |
$0.49 |
| Total Assets | $94.59M +17.9% |
$80.24M +4.4% |
$76.85M -26.9% |
$105.16M +8.1% |
$97.28M +87.4% |
$51.91M |
| Cash and Equivalents | $24.09M +18.6% |
$20.30M -26.0% |
$27.44M -14.3% |
$32.00M -34.8% |
$49.08M +495.2% |
$8.25M |
| Long-Term Debt | $25.28M +1.6% |
$24.88M +70.1% |
$14.62M -26.2% |
$19.83M | — | — |
| Stockholders Equity | $31.85M +58.7% |
$20.07M -1.4% |
$20.35M +19.8% |
$16.98M -59.6% |
$42.04M +308.5% |
$10.29M +274.0% |
| R&D Expense | $480.0K -95.1% |
$9.86M +30.7% |
$7.54M -31.1% |
$10.94M +299.5% |
$2.74M | — |
| Operating Income | -$8.17M +40.3% |
-$13.68M -559.8% |
-$2.07M +92.5% |
-$27.52M +21.1% |
-$34.88M -544.3% |
$7.85M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $17.63M | +20.5% | +17.5% |
| Revenue (ASC 606) | September 30, 2025 | $17.02M | +16.4% | +13.4% |
| Net Income | September 30, 2025 | -$2.31M | +3.1% | +39.0% |
| Diluted EPS | September 30, 2025 | -$0.09 | +25.0% | +43.8% |
| Total Assets | September 30, 2025 | $85.19M | +33.0% | +5.0% |
| Cash and Equivalents | September 30, 2025 | $24.95M | +11.1% | +22.9% |
| Long-Term Debt | September 30, 2025 | $19.53M | -1.3% | -8.6% |
| Stockholders Equity | September 30, 2025 | $25.90M | +137.0% | +34.6% |
| R&D Expense | September 30, 2025 | $287.0K | -65.9% | +635.9% |
| Operating Income | September 30, 2025 | -$1.53M | +47.2% | +46.8% |
| Shares Outstanding | June 30, 2022 | 11.56M | — | +2.1% |
- Journey Medical Corp reported Total Revenue of $61.86 million for fiscal year 2025.
- Journey Medical Corp showed an increase of +10.2% in Total Revenue compared to the prior fiscal year.
- Journey Medical Corp reported Revenue (ASC 606) of $61.24 million for fiscal year 2025.
- Journey Medical Corp showed an increase of +11.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Journey Medical Corp reported Net Income of -$11.43 million for fiscal year 2025.
- Journey Medical Corp showed an increase of +22.1% in Net Income compared to the prior fiscal year.
- Journey Medical Corp reported Diluted EPS of $0.47 per share (loss) for fiscal year 2025.
- Journey Medical Corp showed an increase of +34.7% in Diluted EPS compared to the prior fiscal year.
- Journey Medical Corp reported Total Assets of $94.59 million for fiscal year 2025.
- Journey Medical Corp showed an increase of +17.9% in Total Assets compared to the prior fiscal year.
- Journey Medical Corp reported Cash and Equivalents of $24.09 million for fiscal year 2025.
- Journey Medical Corp showed an increase of +18.6% in Cash and Equivalents compared to the prior fiscal year.
- Journey Medical Corp reported Long-Term Debt of $25.28 million for fiscal year 2025.
- Journey Medical Corp showed an increase of +1.6% in Long-Term Debt compared to the prior fiscal year.
- Journey Medical Corp reported Stockholders Equity of $31.85 million for fiscal year 2025.
- Journey Medical Corp showed an increase of +58.7% in Stockholders Equity compared to the prior fiscal year.
- Journey Medical Corp reported R&D Expense of $480.0 thousand for fiscal year 2025.
- Journey Medical Corp showed a decrease of -95.1% in R&D Expense compared to the prior fiscal year.
- Journey Medical Corp reported Operating Income of -$8.17 million for fiscal year 2025.
- Journey Medical Corp showed an increase of +40.3% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: